|
Management
Goal and Strategies
The Company’s
goal is to have the Company become an industry-leading biotechnology company using the Cell-in-a-Box® technology
as a platform upon which treatments for cancer and diabetes are developed and obtain marketing approval by regulatory agencies
in the United States, the European Union, Australia and Canada.
The Company’s
strategy is to build upon and advance the success of the earlier Phase 1/2 and Phase 2 clinical trials involving advanced pancreatic
cancer. The Company will seek to raise capital to fund growth opportunities in the field of cancer and diabetes and provide for
its immediate working capital needs for both pancreatic cancer and insulin-dependent diabetes. The Company’s strategies
to achieve its goal consists of the following elements:
| |
· |
The completion of the preparations for
the Phase 2b clinical trial in advanced, inoperable pancreatic cancer to be conducted in Australia; |
| |
· |
The completion of the preparations for
the clinical trials that will examine the effectiveness of the Company’s pancreatic cancer treatment in ameliorating
the pain and accumulation of malignant ascites fluid in the abdomen that are characteristic of pancreatic cancer. These clinical
trials will be conducted by TD2 in the United States; |
| |
· |
The completion of preclinical studies
that involve the encapsulation of the Melligen cells using the Cell-in-a-Box® technology to development a treatment
for insulin-dependent diabetes; |
| |
· |
The enhancement of the Company’s
ability to expand into the biotechnology arena through further research and partnering agreements in cancer and diabetes; |
| |
· |
The acquisition of contracts that generate
revenue or provide research and development capital utilizing the Company’s sublicensing rights; |
| |
· |
The further development of uses of the
Cell-in-a-Box® technology platform through contracts, licensing agreements and joint ventures with other companies;
and |
| |
· |
The completion of testing, expansion
and marketing of existing and newly derived product candidates. |
|